Whereas effective in the treatment of some forms of uveitis, current systemic TNFα antagonists are associated with significant safety issues, notably increased risks of serious infections, including tuberculosis, some types of malignancy, and demyelinating disorders.13 The gene discussed is TNF; the disease is uveitis.